Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daylight MAL-PDT versus cryotherapy for prevention of actinic keratosis and non-melanoma skin cancer in transplant patients
2015-002663-42Phase 3Completed
- Sponsor
- Clínica Universidad de Navarra
- Start
- Sep 2015
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of methyl aminolevulinate in actinic keratosis (AK) and non-melanoma skin cancer (NMSC) (2 arms), sponsored by Clínica Universidad de Navarra. Started Sep 2015; status: completed.
02
Drugs
methyl aminolevulinate
03
Conditions
actinic keratosis (AK)non-melanoma skin cancer (NMSC)
Beyond the preview
Go deeper on 2015-002663-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002663-42.